Qing Li

机构：Chinese Academy of Medical Sciences & Peking Union Medical College · ORCID：0000-0002-9258-508X

发表论文 91 篇 · 总被引 2153 次 · h-index 23

代表论文

• Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial (2023 · Acta Pharmaceutica Sinica B · 被引 60)
• Global trends in the burden of ischemic heart disease based on the global burden of disease study 2021: the role of metabolic risk factors (2025 · BMC Public Health · 被引 48)
• Remnant cholesterol inflammatory index and its association with all-cause and cause-specific mortality in middle-aged and elderly populations: evidence from US and Chinese national population surveys (2025 · Lipids in Health and Disease · 被引 37)
• Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer (2023 · Signal Transduction and Targeted Therapy · 被引 15)
• Global trends in the burden of ischemic heart disease attributable to smoking from 1990 to 2021: A systematic analysis of the Global Burden of Disease Study 2021 (2025 · Tobacco Induced Diseases · 被引 13)
• Mic60 is essential to maintain mitochondrial integrity and to prevent encephalomyopathy (2023 · Brain Pathology · 被引 13)